Aims The epidemiology of the five stages of chronic kidney disease (CKD) in systolic heart failure (HF) patients has predominantly been described in hospitalized White patients, with little known ...

Chronic kidney disease affects more than one in four patients from an outpatient systolic HF population, which is higher than the prevalence of CKD in the general population. Chronic kidney ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Background: Approximately 10% of adults in Germany have chronic kidney disease (CKD). The prevalence of CKD among patients being cared for by general practitioners is approximately 30% ...

Not having a formal CKD diagnosis significantly increases ... where the field of epidemiology sparked my fascination. I was eager to explore its real-world implications rather than focusing ...

The global chronic kidney disease treatment market revenue was around US$ 33.2 billion in 2023 and is estimated to reach US$ 47.3 billion by 2032, growing at a compound annual growth rate (CAGR) of 4% ...

Taking charge of your health is one of the most powerful choices you can make, and prioritising your kidneys plays a vital ...

Semaglutide was also found to be superior to placebo for the confirmatory secondary endpoints, which included annual rate of change in eGFR (CKD-EPI), time to occurrence of a major adverse CV ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...